These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A Key Role of DNA Damage-Inducible Transcript 4 (DDIT4) Connects Autophagy and GLUT3-Mediated Stemness To Desensitize Temozolomide Efficacy in Glioblastomas. Ho KH; Chen PH; Chou CM; Shih CM; Lee YT; Cheng CH; Chen KC Neurotherapeutics; 2020 Jul; 17(3):1212-1227. PubMed ID: 31916238 [TBL] [Abstract][Full Text] [Related]
3. CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells. Maciaczyk D; Picard D; Zhao L; Koch K; Herrera-Rios D; Li G; Marquardt V; Pauck D; Hoerbelt T; Zhang W; Ouwens DM; Remke M; Jiang T; Steiger HJ; Maciaczyk J; Kahlert UD Br J Cancer; 2017 Jun; 117(1):102-112. PubMed ID: 28571041 [TBL] [Abstract][Full Text] [Related]
4. The HIF‑1α/miR‑224‑3p/ATG5 axis affects cell mobility and chemosensitivity by regulating hypoxia‑induced protective autophagy in glioblastoma and astrocytoma. Huang S; Qi P; Zhang T; Li F; He X Oncol Rep; 2019 Mar; 41(3):1759-1768. PubMed ID: 30569180 [TBL] [Abstract][Full Text] [Related]
5. ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma. Dréan A; Rosenberg S; Lejeune FX; Goli L; Nadaradjane AA; Guehennec J; Schmitt C; Verreault M; Bielle F; Mokhtari K; Sanson M; Carpentier A; Delattre JY; Idbaih A J Neurooncol; 2018 Jul; 138(3):479-486. PubMed ID: 29520610 [TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible lncRNA MIR210HG interacting with OCT1 is involved in glioblastoma multiforme malignancy. Ho KH; Shih CM; Liu AJ; Chen KC Cancer Sci; 2022 Feb; 113(2):540-552. PubMed ID: 34897892 [TBL] [Abstract][Full Text] [Related]
7. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2. Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849 [TBL] [Abstract][Full Text] [Related]
8. Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells. Fabro F; Kers TV; Feller KJ; Beerens C; Ntafoulis I; Idbaih A; Verreault M; Connor K; Biswas A; Salvucci M; Prehn JHM; Byrne AT; O'Farrell AC; Lambrechts D; Dilcan G; Lodi F; Arijs I; Kremer A; Tching Chi Yen R; Chien MP; Lamfers MLM; Leenstra S Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958662 [TBL] [Abstract][Full Text] [Related]
9. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of SIRT1/2 upregulates HSPA5 acetylation and induces pro-survival autophagy via ATF4-DDIT4-mTORC1 axis in human lung cancer cells. Mu N; Lei Y; Wang Y; Wang Y; Duan Q; Ma G; Liu X; Su L Apoptosis; 2019 Oct; 24(9-10):798-811. PubMed ID: 31321634 [TBL] [Abstract][Full Text] [Related]
11. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway. Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149 [TBL] [Abstract][Full Text] [Related]
12. Transcriptional control of O Happold C; Stojcheva N; Silginer M; Weiss T; Roth P; Reifenberger G; Weller M J Neurochem; 2018 Mar; 144(6):780-790. PubMed ID: 29480969 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation. Liang H; Chen Z; Sun L Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274 [TBL] [Abstract][Full Text] [Related]
14. Hyperoxia resensitizes chemoresistant glioblastoma cells to temozolomide through unfolded protein response. Lee D; Sun S; Ho AS; Kiang KM; Zhang XQ; Xu FF; Leung GK Anticancer Res; 2014 Jun; 34(6):2957-66. PubMed ID: 24922660 [TBL] [Abstract][Full Text] [Related]
15. NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma. Weiss T; Schneider H; Silginer M; Steinle A; Pruschy M; Polić B; Weller M; Roth P Clin Cancer Res; 2018 Feb; 24(4):882-895. PubMed ID: 29162646 [No Abstract] [Full Text] [Related]
16. A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia. Musah-Eroje A; Watson S J Neurooncol; 2019 Apr; 142(2):231-240. PubMed ID: 30694423 [TBL] [Abstract][Full Text] [Related]
17. Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme. Hsieh CH; Lin YJ; Wu CP; Lee HT; Shyu WC; Wang CC Clin Cancer Res; 2015 Jan; 21(2):460-70. PubMed ID: 25370472 [TBL] [Abstract][Full Text] [Related]
18. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling. Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594 [TBL] [Abstract][Full Text] [Related]
19. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide. Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181 [TBL] [Abstract][Full Text] [Related]
20. Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma. Yamini B; Yu X; Gillespie GY; Kufe DW; Weichselbaum RR Cancer Res; 2004 Sep; 64(18):6381-4. PubMed ID: 15374943 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]